Matinas achieves statistical endpoint for success in MAT2203 Phase 2a study
Matinas BioPharma announced that investigators from the National Institutes of Health have relayed to the company positive data from a third patient enrolled in the collaborative Phase 2a clinical study of Matinas' lead anti-infective product candidate MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis infection. This third patient, with long-standing azole resistant mucocutaneous candidiasis, met the primary endpoint of the Phase 2a study in achieving greater than or equal to 50% clinical response with treatment of MAT2203. MAT2203 was well tolerated with any adverse events observed being mild in severity and unrelated to study drug. With this third positive response, the study has met its statistical hurdle for success. MAT2203 is the company's orally-administered, encochleated formulation of the broad spectrum fungicidal medication amphotericin B. Matinas BioPharma's proprietary lipid-crystal nano-particle formulation of amphotericin B has a novel mechanism of absorption and distribution to infected tissues and has the potential to transform the way this potent fungicidal agent is administered and used in clinical practice.